Prospective Evaluation of Forceplate Measured Levodopa-Induced Dyskinesia

Parkinson's Disease Clinical Trial

Official title:

Prospective Evaluation of Forceplate Measured Levodopa-Induced Dyskinesia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00912977
• Other study ID #: e5348
• Status: Completed
• Phase: N/A
• First received: June 2, 2009
• Last updated: September 29, 2016
• Start date: June 2009
• Est. completion date: June 2010

Study information

• Verified date: September 2016
• Source: Oregon Health and Science University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Nearly all Parkinson's disease (PD) patients eventually develop abnormal and unwanted movements (dyskinesias; LID) caused by the gold standard treatment, Levodopa. The severity of these movements can range from subtle to extremely debilitating and may or may not interfere with normal activities such as putting on a coat or brushing ones teeth. The purpose of this study is to demonstrate the validity and reliability of objectively measuring dyskinesia with a forceplate.

Description:

The main outcome measure of this study are measurements taken every half hour during an inpatient study visit. These measurements include standing on a forceplate for 1 minute while performing a mental task such as reciting the alphabet backwards. During this forceplate stance, a rater will visually score your movements. All participants must be eligible for another Parkinson's disease study at Oregon Health and Science University.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: June 2010
• Est. primary completion date: June 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Parkinsons disease

• Older than 18

Exclusion Criteria:

• Must be participating in a Parkinsons disease study at Oregon Health & Science University

Study Design

Observational Model: Case-Crossover, Time Perspective: Prospective

Related Conditions & MeSH terms

• Dyskinesias
• Parkinson Disease
• Parkinson's Disease

Locations

Country	Name	City	State
United States	Oregon Health & Science University	Portland	Oregon

Sponsors (1)

Lead Sponsor	Collaborator
Oregon Health and Science University

Country where clinical trial is conducted

United States, 

References & Publications (3)

Durif F, Debilly B, Galitzky M, Morand D, Viallet F, Borg M, Thobois S, Broussolle E, Rascol O. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology. 2004 Feb 10;62(3):381-8. — View Citation

Durif F, Vidailhet M, Debilly B, Agid Y. Worsening of levodopa-induced dyskinesias by motor and mental tasks. Mov Disord. 1999 Mar;14(2):242-5. — View Citation

Hagell P, Widner H. Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale. Mov Disord. 1999 May;14(3):448-55. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Forceplate Measure		Every 1/2 hour	No
Secondary	Visual Rating Scale		every 1/2 hour	No